91AV

Introduction

Oxford Global are proud to present the 2nd Annual Advances in Immuno-Oncology Congress, taking place 15-16 May 2017 in London UK. The event features 200 delegates from world renowned academic institutions, hospitals, global pharmaceutical organisations and leading biotechnology companies. 36 presentations and case studies will focus on the key developments in Immuno-Oncology with specific reference to the discovery of therapeutic areas, pre-clinical and clinical studies, screening, assays and modelling.
 
The congress has 4 interactive streams:

• Discovery of Immuno-Oncology Therapies
• Pre-clinical Immuno-Oncology
• Screening, Assays and Modelling in Immuno-Oncology
• Immuno-Oncology: Therapeutic Approaches, Clinical Research and Clinical Trials

14 pre-scheduled one to one meetings, exhibition and informal networking opportunities.

2017 Speakers Include:

• Philip Arlen, President and CEO, Precision Biologics, Inc.
• Jakob Dupont, Senior Vice President & Chief Medical Officer, OncoMed Pharmaceuticals
• Anne Altmeyer, Vice President, Business Development, Negotiations, Baxalta
• Graham Pockley, CEO Multimmune GmbH
• Ulf Grawunder, CEO, NBE Therapeutics
• Jonathan Zalevsky, Vice President, Biology & Preclinical Development, Nektar Therapeutics
• Gavin Thurston/Regeneron rep, Vice President, Oncology and Angiogenesis Research, Regeneron Pharmaceuticals 

Useful links

Speakers

• Philip Arlen President and CEO, Precision Biologics, Inc., United Kingdom
• Jakob Dupont Senior Vice President & Chief Medical Officer, OncoMed Pharm, United Kingdom
• Anne Altmeyer Vice President, Business Development, Negotiations, Baxalta, United Kingdom
• Graham Pockley CEO Multimmune GmbH, United Kingdom

---

Venue

Copthorne Tara Hotel

Copthorne Tara Hotel, Copthorne Tara Hotel, Scarsdale Place , Kensington , London, W8 5SR, United Kingdom

Organised by

Oxford Global

Contact information

Danielle Dalby
Oxford Global
01865248455
Contact us by email

---